Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
1927 1
1934 1
1957 3
1958 1
1959 1
1961 1
1965 1
1970 2
1982 1
1987 1
1988 2
1991 1
1992 4
1993 2
1995 4
1997 2
1998 6
1999 6
2000 2
2001 1
2002 3
2003 10
2004 16
2005 16
2006 42
2007 47
2008 47
2009 16
2010 8
2011 12
2012 10
2013 15
2014 26
2015 19
2016 19
2017 17
2018 18
2019 12
2020 12
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 18434616

372 results
Results by year
Filters applied: . Clear all
Page 1
Role of vasopressin antagonists.
Torres VE. Torres VE. Clin J Am Soc Nephrol. 2008 Jul;3(4):1212-8. doi: 10.2215/CJN.05281107. Epub 2008 Apr 23. Clin J Am Soc Nephrol. 2008. PMID: 18434616 Free article. Review.
Vasopressin antagonists in polycystic kidney disease.
Torres VE. Torres VE. Semin Nephrol. 2008 May;28(3):306-17. doi: 10.1016/j.semnephrol.2008.03.003. Semin Nephrol. 2008. PMID: 18519091 Free PMC article. Review.
Introduction: new insights, treatments, and management strategies for ADPKD.
Cowley BD Jr. Cowley BD Jr. Clin J Am Soc Nephrol. 2008 Jul;3(4):1195-6. doi: 10.2215/CJN.00460108. Epub 2008 Mar 5. Clin J Am Soc Nephrol. 2008. PMID: 18322052 Free article. No abstract available.
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Torres VE, et al. Nat Med. 2004 Apr;10(4):363-4. doi: 10.1038/nm1004. Epub 2004 Feb 29. Nat Med. 2004. PMID: 14991049
Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X, Harris PC, Somlo S, Batlle D, Torres VE. Wang X, et al. Nephrol Dial Transplant. 2009 Feb;24(2):526-34. doi: 10.1093/ndt/gfn527. Epub 2008 Sep 30. Nephrol Dial Transplant. 2009. PMID: 18826972 Free PMC article.
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
Gattone VH 2nd, Wang X, Harris PC, Torres VE. Gattone VH 2nd, et al. Nat Med. 2003 Oct;9(10):1323-6. doi: 10.1038/nm935. Epub 2003 Sep 21. Nat Med. 2003. PMID: 14502283
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS. Irazabal MV, et al. Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4. Kidney Int. 2011. PMID: 21544064 Free article. Clinical Trial.
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Wang X, Gattone V 2nd, Harris PC, Torres VE. Wang X, et al. J Am Soc Nephrol. 2005 Apr;16(4):846-51. doi: 10.1681/ASN.2004121090. Epub 2005 Feb 23. J Am Soc Nephrol. 2005. PMID: 15728778 Free article.
Effects of hydration in rats and mice with polycystic kidney disease.
Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. Hopp K, et al. Am J Physiol Renal Physiol. 2015 Feb 1;308(3):F261-6. doi: 10.1152/ajprenal.00345.2014. Epub 2014 Dec 10. Am J Physiol Renal Physiol. 2015. PMID: 25503729 Free PMC article.
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Torres VE, et al. Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17. Am J Kidney Dis. 2011. PMID: 21333426 Clinical Trial.
372 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback